Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Given Consensus Rating of “Strong Sell” by Brokerages

Shares of Carl Zeiss Meditec AG (OTCMKTS:CZMWY) have been assigned a consensus recommendation of “Strong Sell” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the company.

Several research analysts have commented on CZMWY shares. UBS Group cut shares of Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a report on Tuesday, August 11th. Morgan Stanley initiated coverage on shares of Carl Zeiss Meditec in a report on Wednesday, September 2nd. They set an “underweight” rating on the stock. Finally, Zacks Research downgraded shares of Carl Zeiss Meditec from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 11th.

Carl Zeiss Meditec Stock Down 2.0%

Shares of OTCMKTS:CZMWY opened at $35.15 on Friday. The company has a 50 day moving average of $35.07 and a 200-day moving average of $31.73. Carl Zeiss Meditec has a twelve month low of $26.65 and a twelve month high of $55.94.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.